BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 30110720)

  • 1. Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.
    Jung IY; Lee J
    Mol Cells; 2018 Aug; 41(8):717-723. PubMed ID: 30110720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene editing and CRISPR in the clinic: current and future perspectives.
    Hirakawa MP; Krishnakumar R; Timlin JA; Carney JP; Butler KS
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32207531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
    Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
    Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
    Quazi S
    Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9: an advanced tool for editing plant genomes.
    Samanta MK; Dey A; Gayen S
    Transgenic Res; 2016 Oct; 25(5):561-73. PubMed ID: 27012546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
    Jensen TI; Axelgaard E; Bak RO
    Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Gene Editing with CRISPR: A Laboratory Medicine Perspective.
    Hahn E; Hiemenz M
    Clin Lab Med; 2020 Jun; 40(2):205-219. PubMed ID: 32439069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Gene Editing Approaches to Fine-Tune the Immune System.
    Pavlovic K; Tristán-Manzano M; Maldonado-Pérez N; Cortijo-Gutierrez M; Sánchez-Hernández S; Justicia-Lirio P; Carmona MD; Herrera C; Martin F; Benabdellah K
    Front Immunol; 2020; 11():570672. PubMed ID: 33117361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
    Eid A; Mahfouz MM
    Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
    Li C; Mei H; Hu Y
    Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Genome Editing and its Potential Enhancement through CRISPR Guide RNA and Cas9 Modifications.
    Batzir NA; Tovin A; Hendel A
    Pediatr Endocrinol Rev; 2017 Jun; 14(4):353-363. PubMed ID: 28613045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
    Ren J; Zhao Y
    Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research on genodermatoses using novel genome-editing tools.
    Lehmann J; Seebode C; Emmert S
    J Dtsch Dermatol Ges; 2017 Aug; 15(8):783-789. PubMed ID: 28622433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome editing comes of age.
    Kim JS
    Nat Protoc; 2016 Sep; 11(9):1573-8. PubMed ID: 27490630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.